4 Feb 2015 07:00
Wednesday 4 February 2015
SYNERGY HEALTH PLC("Synergy" or "the Company")
Q3 Interim Management Statement
Synergy (SYR.L), a leading provider of specialist outsourced support services to health-related markets is pleased to provide an update on trading performance since 28 September 2014.
Trading Performance Update
Synergy is trading in line with the Board's expectations for the full year.
Reported revenue for the nine months to 28 December 2014 increased by 5.7% to £303.1 million (Q3 2013/14 £286.9 million). Underlying revenue, excluding currency effects, increased by 9.6%. Growth has been building throughout the year, with third quarter underlying revenues before currency effects up 14.2% on the same period in 2013. Operating margin remains 50 basis points higher than the comparative period.
Revenue in the operating businesses is analysed as follows:
Reported revenue | Q32014/15(million) | Q32013/14(million) | Growth% | Underlying growth %(ex-currency) | Q3 YTD2014/15(million) | Q3 YTD2013/14(million) | Growth% | Underlying growth %(ex-currency) |
Applied Sterilisation Technologies | £35.1 | £29.6 | 18.6% | 23.2% | £102.2 | £90.0 | 13.5% | 19.3% |
Hospital Sterilisation Services | £46.2 | £39.7 | 16.5% | 16.7% | £129.1 | £121.1 | 6.7% | 9.4% |
Healthcare Solutions | £24.3 | £25.4 | (4.6%) | (0.3%) | £71.8 | £75.8 | (5.3%) | (1.5%) |
Total | £105.6 | £94.7 | 11.5% | 14.2% | £303.1 | £286.9 | 5.7% | 9.6% |
For Further Information:
Synergy Health plc | |
Richard Steeves, Chief ExecutiveGavin Hill, Finance Director | Tel: +44 (0) 1793 891 891 |
Investec | |
Patrick Robb | Tel: +44 (0) 20 7597 5970 |
SYR.L (SYR)